About Micreos
Micreos is a Healthcare company based in The Hague (Netherlands) founded in 2005. It develops targeted antibacterial products to replace antibiotics. Micreos has raised $108.97 million across 10 funding rounds from investors including Altria, European Union and Oost NL. Its chief executive, as recorded, is Mark Offerhaus. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is Micreos Pharmaceuticals AG.
Company details
Micreos develops targeted antibacterial products to replace antibiotics. The company provides Micreos endolysin technology that can kill unwanted bacteria including antibiotic-resistant strains while leaving the beneficial bacteria intact. The company is also involved in the development of Micreos Staphefekt SA.100 enzyme (endolysin), which can kill Staphylococcus aureus and MRSA. It is also suitable for routine maintenance therapy, for people with skin conditions with an infectious component, such as acne, eczema, psoriasis, and rosacea. The compnay products are FDA-approved.
- Headquarters The Hague, Netherlands
- SectorsHealthcare
- Email••••••••
- Website micreos.com
- Social LinkedIn X
- Legal Name Micreos Pharmaceuticals Ag
- Total Equity Funding$108.97M (USD)
in 10 rounds
- Latest Funding Round$24.63M (USD), Series D
Oct 2022
- InvestorsAltria
& 4 more
Funding Insights of Micreos
Micreos has successfully raised a total of $108.97M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $24.63 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $108.97M
- Total Rounds 10
- Last Round Series D — $24.63M
- Investors Count 5
All 10 funding rounds of Micreos with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
5 investors in total: 5 institutional.
Investors in Micreos
Micreos has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Altria, European Union and Oost NL.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Sector-agnostic VC firm investing in geographies such as the Netherlands | 2003 | oostnl.nl | Apeldoorn, Netherlands | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Official information and services are provided by the Dutch government. | government.nl | Netherlands | ||
Tobacco products are manufactured and distributed by Altria through subsidiaries. | 1919 | altria.com | Richmond, United States |
Investor details for Micreos
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Micreos
1 people are tracked at Micreos (1 in leadership).
| Name | Role | Group |
|---|---|---|
Mark Offerhaus | CEO | Leadership |
Complete people profiles for Micreos
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Micreos
3 dated milestones of Micreos across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Micreos is founded.
- Funding First funding round.
- Funding Latest funding round, Series D, of $24.6M.
Web traffic of Micreos
Websites that share an audience with Micreos (micreos.com).
Websites whose visitors overlap most with Micreos. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| gladskin.com | 100% | 48.4K | #705,521 | View details | |
micreosfoodsafety.com | micreosfoodsafety.com | 63% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Micreos
Complete news archive for Micreos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Micreos
Micreos was founded in 2005 and raised its 1st funding round 7 years after it was founded.
Micreos is headquartered in The Hague, Netherlands. It is registered at The Hague, South Holland, Netherlands.
Mark Offerhaus is the CEO of Micreos, as recorded in our data.
Micreos is a funded company, having raised a total of $108.97M across 10 funding rounds to date.
Micreos develops targeted antibacterial products to replace antibiotics. The company provides Micreos endolysin technology that can kill unwanted bacteria including antibiotic-resistant strains while leaving the beneficial bacteria intact. The company is also involved in the development of Micreos Staphefekt SA.100 enzyme (endolysin), which can kill Staphylococcus aureus and MRSA. It is also suitable for routine maintenance therapy, for people with skin conditions with an infectious component, such as acne, eczema, psoriasis, and rosacea. The compnay products are FDA-approved.
Micreos has 5 investors. Key investors include Altria, European Union, Oost NL, EIC Fund, and Government of the Netherlands.
Micreos operates through Micreos Pharmaceuticals Ag.